公开(公告)号：US20220024918A1

公开(公告)日：2022-01-27

申请号：US17368712

申请日：2021-07-06

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Dong Hoon KIM ,  Su Bin CHOI ,  Sol PARK ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC: C07D471/04 ,  C07D519/00

Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20230086884A1

公开(公告)日：2023-03-23

申请号：US17822450

申请日：2022-08-26

Applicant: YUHAN CORPORATION ,  JANSSEN BIOTECH, INC.

Inventor： Byoungmoon LEE ,  Hyunjoo LEE ,  Gyu Jin LEE ,  Su Bin CHOI ,  Sol PARK ,  Heejun KIM ,  Misong KIM ,  Young Ae YOON ,  Kwan Hoon HYUN ,  Tae Kyun KIM ,  Jae Young SIM ,  Marian C. BRYAN ,  Scott KUDUK ,  James Campbell ROBERTSON

IPC: C07D401/14

Abstract: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

公开(公告)号：US20230086795A1

公开(公告)日：2023-03-23

申请号：US17822438

申请日：2022-08-26

Applicant: YUHAN CORPORATION ,  JANSSEN BIOTECH, INC.

Inventor： Hyunjoo LEE ,  Su Bin CHOI ,  Young Ae YOON ,  Kwan Hoon HYUN ,  Jae Young SIM ,  Marian C. BRYAN ,  Scott KUDUK ,  James Campbell Robertson ,  Jaekyoo LEE ,  Paresh Devidas SALGAONKAR ,  Byung-Chul SUH ,  Jong Sung KOH ,  So Young HWANG

IPC: C07D401/14

Abstract: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

公开(公告)号：US20230085912A1

公开(公告)日：2023-03-23

申请号：US17822443

申请日：2022-08-26

Applicant: YUHAN CORPORATION ,  JANSSEN BIOTECH, INC.

Inventor： Byoungmoon LEE ,  Hyunjoo LEE ,  Gyu Jin LEE ,  Su Bin CHOI ,  Misong KIM ,  Young Ae YOON ,  Kwan Hoon HYUN ,  Jae Young SIM ,  Marian C. BRYAN ,  Scott KUDUK ,  James Campbell ROBERTSON ,  Jaekyoo LEE ,  Paresh Devidas SALGAONKAR ,  Byung-Chul SUH ,  Jong Sung KOH ,  So Young HWANG

IPC: C07D401/14

Abstract: Provided are 5-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

公开(公告)号：US20210147368A1

公开(公告)日：2021-05-20

申请号：US17104557

申请日：2020-11-25

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Su Bin CHOI ,  Dong Hoon KIM ,  Sol PARK ,  Eun Hye JUNG ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC: C07D249/08 ,  C07D401/04 ,  C07D403/04 ,  C07D417/04 ,  C07D409/10 ,  C07D405/10 ,  C07D407/14 ,  C07D401/10 ,  C07D403/10 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D413/10 ,  C07D417/10 ,  C07D249/12 ,  C07D403/14

Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20200223844A1

公开(公告)日：2020-07-16

申请号：US16712673

申请日：2019-12-12

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Dong Hoon KIM ,  Su Bin CHOI ,  Sol PARK ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC: C07D471/04 ,  C07D519/00

Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20230090406A1

公开(公告)日：2023-03-23

申请号：US17822445

申请日：2022-08-26

Applicant: YUHAN CORPORATION ,  JANSSEN BIOTECH, INC.

Inventor： Hyunjoo LEE ,  Su Bin CHOI ,  Misong KIM ,  Young Ae YOON ,  Kwan Hoon HYUN ,  Jae Young SIM

IPC: C07D401/14 ,  C07D413/14

Abstract: Provided are 6-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

公开(公告)号：US20210317110A1

公开(公告)日：2021-10-14

申请号：US17208887

申请日：2021-03-22

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Su Bin CHOI ,  Sol PARK ,  Dong Hoon KIM ,  So Young KIM ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA ,  Eui Chul LEE

IPC: C07D409/04 ,  C07D409/14 ,  C07D498/04 ,  C07D413/14 ,  C07D471/04 ,  C07D405/14

Abstract: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g. for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20200223808A1

公开(公告)日：2020-07-16

申请号：US16721020

申请日：2019-12-19

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Su Bin CHOI ,  Dong Hoon KIM ,  Sol PARK ,  Eun Hye JUNG ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC: C07D249/08 ,  C07D401/04 ,  C07D403/04 ,  C07D417/04 ,  C07D409/10 ,  C07D405/10 ,  C07D407/14 ,  C07D401/10 ,  C07D403/10 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D413/10 ,  C07D417/10 ,  C07D249/12 ,  C07D403/14

Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20190322655A1

公开(公告)日：2019-10-24

申请号：US16359985

申请日：2019-03-20

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Su Bin CHOI ,  Sol PARK ,  Dong Hoon KIM ,  So Young KIM ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA ,  Eui Chul LEE

IPC: C07D409/04 ,  C07D409/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

Abstract: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).